ICLUSIG (Ponatinib) Tablets
Description of Iclusig (Ponatinib)
Iclusig is a prescription medicine used to treat adults who have chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) or Philadelphia chromosome (Ph+) acute lymphoblastic leukemia (ALL) who are no longer benefiting from previous treatment, or who did not tolerate other treatment
Its use and Indications
Iclusig® is a kinase inhibitor indicated for the:
Treatment of adult patients with T3151-positive chronic myeloid leukemia (CML) (chronic phase, accelerated phase, or blast phase) or
T3151-philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) –positive ace
- Treatment of adult patients with chronic phase, accerated phase, or blast phase chronic myeloid leukemia or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) is indicated
For treatment related information, please consult your treating Physician.
Iclusig is supplied in high density polyethylene (HDPE) bottles with screw-top closures, containing either
- Iclusig 15 mg – 60 or 180 film coated tablets
- Iclusig 45 mg – 30 or 90 film coated tablets
Storage and handling
Store in the original container in order to protect from light. It can be stored at room temperature
How do we source the Drug?
Super Specialities Pharma will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is also essential.
Company that Manufactures/ Markets:
M/s ARIAD Pharma (UK) Ltd
Mob No: +91 7738100125, +91 7738151650
E Mail: email@example.com